SALICYLIC ACID

Manufacturer
Acella Pharmaceuticals, LLC | Span Packaging Services LLC
Effective date
2024-05-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
legacy-cache
Hydrated at
2026-08-01 21:02:19

Label at a glance#

ProductSALICYLIC ACID
Active ingredientSALICYLIC ACID
Label structure19 sections

Label contents#

Full prescribing information#

DESCRIPTION SECTION

DESCRIPTION

Salicylic Acid 6% Foam is applied topically and used in the removal of excessive keratin in hyperkeratotic skin disorders. Each gram of Salicylic Acid 6% Foam contains salicylic
acid 6% as the active ingredient, and the following inactive ingredients: dimethicone, ethylparaben, glycerin, methylcellulose, methylparaben, phenoxyethanol, polyoxyl 40 stearate,
polysorbate 20, polysorbate 80, povidone, propylene glycol, propylparaben, purified water, sodium citrate, sodium hydroxide, stearic acid and trolamine and in propellants butane
and propane.

SPL UNCLASSIFIED SECTION

CHEMICAL STRUCTURE

Salicylic acid is a 2-hydroxy derivative of benzoic acid having the following chemical structure:

structurestructure

CLINICAL PHARMACOLOGY SECTION

Salicylic acid has been shown to produce desquamation of the horny layer of skin while not affecting qualitative or quantitative changes in structure of the viable epidermis. The
mechanism of action has been attributed to dissolution of intercellular cement substance. In a study of the percutaneous absorption of salicylic acid from Salicylic Acid 6% Foam in
four patients with extensive active psoriasis, Taylor and Halprin showed that peak serum levels never exceeded 5 mg/100 mL even though more than 60% of the applied salicylic
acid was absorbed. Systemic toxic reactions are usually associated with much higher serum leverls (30 to 40 mg/100mL). Peak serum levels occurred within 5 hours of the topical
application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients
with a contracted extracellular space due to dehydration or diuretics have higher salicylate levels than those with a normal extracellular space. (See PRECAUTIONS).
The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%), and free salicylic acid (6%). The urinary
metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more glucuronides and less
salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space.
Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs. By similar
competetive mechanisms other drugs can influence the serum levels of salicylate. (See PRECAUTIONS).

PHARMACOKINETICS SECTION

The mechanism of action of topically applied salicylic acid has been attributed to the dissolution of intercellular cement substance.

INDICATIONS & USAGE SECTION

INDICATIONS AND USAGE

For Dermatologic Use: Salicylic Acid 6% Foam is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses,
keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris and psoriasis.

For Podiatric Use: Salicylic Acid 6% Foam is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions.

CONTRAINDICATIONS SECTION

CONTRAINDICATIONS

Salicylic Acid 6% Foam should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. Salicylic Acid 6% Foam should not be used in
children under 2 years of age.

WARNINGS SECTION

WARNINGS

Salicylic Acid 6% Foam is for external use only. It is not for ophthalmic, oral, anal or intravaginal use. Contact with eyes, lips, broken or inflamed skin, and all mucous membranes
should be avoided. Salicylic Acid 6% Foam should not be used by persons who have a known hypersensitivity to salicylic acid or any of the other listed ingredients.
Prolonged use over large areas, especially in children and those patients with significant renal or hepatic impairment could result in salicylism. Concomitant use of other drugs
which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal
or hepatic impairment, the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity: nausea, vomiting, dizziness, loss of hearing, tinnitus,
lethargy, hyperpnoea, diarrhea, psychic disturbances. In the event of salicylic acid toxicity, the use of Salicylic Acid 6% Foam should be discontinued. Fluids should be administered
to promote urinary excretion. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate.
Condidering the potential of developing Reye’s syndrome, salicylate products should not be administered to children or teenagers with varicella or influenza, unless directed by a
physician.

PRECAUTIONS SECTION

PRECAUTIONS 
Salicylic Acid 6% Foam should be used only as directed by a physician and should not be used to treat any condition other than that for which it is prescribed. Salicylic Acid 6%
Foam should not be used on any skin area where inflammation or exudation is present as increased absorption may occur. If redness or irritation occurs, discontinue use and
consult with prescribing physician.

DRUG INTERACTIONS SECTION

DRUG INTERACTIONS

(The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these

interactions to the use of Salicylic Acid 6% Foam is not known.)

I. Due to the competition of salicylate with other drugs for binding to serum albumin, the following drug interactions may occur:

Drug Description of Interaction

Tolbutamide; Sulfonylureas Hypoglycemia potentiated

Methotrexate Decrease tubular reabsorption; clinical toxicity from methotrexate can result

Oral Anticoagulants Increased bleeding

II. Drugs changing salicylate levels by altering renal tubular reabsorption: Drug Description

Corticosteroids Decreases plasma salicylate level; tapering doses of steroids may promote salicylism

Ammonium Sulfate Increases plasma salicylate level

III. Drugs with complicated interactions with salicylates:

Drug Description

Heparin Salicylate decreases platelet adhesivesness and interferes with hemostasis in

heparin-treated patients

Pyrazinamide Inhibits pyrazinamide-induced hyperuricemia

Uricosuric Agents Effect of probenecid, sulfinpyrazone and phenylbutazone inhibited

LABORATORY TESTS SECTION

The following alterations of laboratory tests have been reported during salicylate therapy:
                 Laboratory Tests                                                               Effect of Salicylates

                   Thyroid Function                                                                                      Decreased PBI; increased T3 uptake

                    Urinary Sugar                                                                                         False negative with glucose oxidase; false positive with Clinitest with high-dose salicylat
                                                                                                                                 therapy (2 - 5 g qd)                                                                                                                    
                    5 Hydroxyindole Acetic Acid                                                                    False negative with fluorometric test

                   Acetone, Ketone Bodies                                                                           False positive FeCl3 in Gerhardt reaction; red color persists with boiling

                   17-OH Corticosteroids                                                                              False reduced values with >4.8 g qd salicylate

                    Vanilmandelic Acid                                                                                 False reduced values

                    Uric Acid                                                                                                May increase or decrease depending on dose

                    Prothrombin                                                                                            Decreased levels; slightly increased prothrombin time

PREGNANCY SECTION

Pregnancy (Category C) - Orally administered salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid
used in these studies to topical administration as the oral dose to monkeys may represent 4 times the maximum daily human dose of salicylic acid (as supplied in one tube, 40 g of
Salicylic Acid 6% Gel) when applied topically over a large body surface. There are no adequate and well-controlled studies in pregnant women. Salicylic Acid 6% Foam should be
used during pregnancy only if the potential benefit justifies the risk to the fetus.

NURSING MOTHERS SECTION

Nursing Mothers - It is not known whether topically applied salicylic acid is excreted in human milk. Due to the fact that many drugs are excreted in human milk, caution should be
exercised by physicians when administering Salicylic Acid 6% Foam to nursing mothers and nursing mothers should certainly not apply Salicylic Acid 6% Foam to the chest area or
any other part of the body with which the nursing child’s mouth is likely to come in contact.
Because of the potential for serious advers reactions in nursing infants from the mother’s use of Salicylic Acid 6% Foam, a decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the drug to the mother.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

 No data are available concerning the potential carcinogenic or reproductive effects of Salicylic Acid 6% Foam. It has been
shown to lack mutagenic potential in the Ames Salmonella test.

GENERAL PRECAUTIONS SECTION

KEEP THIS AND ALL OTHER MEDICATIONS OUT OF THE REACH OF CHILDREN.

ADVERSE REACTIONS SECTION

Transient stinging, burning, itching or irritation is possible. Peeling of the skin may increase as the salicylic acid works to loosen excess keratin. If excessive burning, stinging or
peeling occurs, discontinue use and consult a physician.

DOSAGE & ADMINISTRATION SECTION

Unless otherwise directed by a prescribing physician, Salicylic Acid 6% Foam should be applied to the affected area twice a day. Salicylic Acid 6% Foam should be rubbed into the
skin until it is completely absorbed.

Salicylic Acid 6% Foam should be shaken vigorously before each application and inverted to administer.

HOW SUPPLIED SECTION

Salicylic Acid 6% Foam is supplied in a 70 gram or 2.5 ounce aerosolized canister bearing the NDC# 42192-112-70.

Store at controlled room temperature 15° - 25°C(59° - 77°F).

Contains flammable materials. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose to temperatures over 120°F (48°C) even when empty.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42192-112-70

SALICYLIC ACID 6% FOAM

Hydrating Topical Foam

Rx Only

Net wt. 2.5 oz (70g)

Acella Pharmaceuticals


Dosage and Administration: Apply Salicylic Acid 6% foam topically to cover affected skin twice per day, or as directed by a physician. Rub in until completely absorbed.

Shake vigorously before each application and invert can to administer.

Store at room temperature 59degrees to 77 degrees F (15degrees to 15 degrees C)

See prescribing information for additional details.

Ingredients: Salicylic Acid 6%, Dimethicone, Ethylparaben, Glycerin, Methylcellulose, Methylparabaen, Phenoxyethanol, Polyoxyl 40 Stearate, Polysorbate 20, Polysorbate 80, Povidone, Propylene Glycol, Propylparaben, Purified Water, Sodium citrate, Sodium Hydroxide, Stearic Acid, and Trolamine and in propellants Butane and Propane.



Warning: contains flammable materials. Contents under pressure. Do not puncture or incinerate. Do not expose to temperatures over 120 degrees F (48 degrees C) even when empty. Keep out of reach of children.



Manufactured for

Acella Pharmaceuticals, LLC

Alpharetta, GA 30009

1-800-541-4802

Rev 0909v4

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PrimaryPrimaryStructureStructure

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
42192-112SALICYLIC ACID AEROSOL, FOAM [ACELLA PHARMACEUTICALS, LLC]9Legacy NDC20240522_cb0820e8-de07-4403-af3a-13986e86493e.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
42192-112-70GM - Gram42192-11296494ca3-f45a-44cf-89f5-25ed5113ea4c12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
SALICYLIC ACIDACTIVE INGREDIENTO414PZ4LPZ4
SALICYLIC ACIDACTIVE MOIETYO414PZ4LPZ4
BUTANEINACTIVE INGREDIENT6LV4FOR43R4
DIMETHICONEINACTIVE INGREDIENT92RU3N3Y1O4
ETHYLPARABENINACTIVE INGREDIENT14255EXE394
GLYCERININACTIVE INGREDIENTPDC6A3C0OX4
METHYLCELLULOSE (100 CPS)INACTIVE INGREDIENT4GFU244C4J4
PHENOXYETHANOLINACTIVE INGREDIENTHIE492ZZ3T4
POLYOXYL 40 STEARATEINACTIVE INGREDIENT13A4J4NH9I4
Polysorbate 20INACTIVE INGREDIENT7T1F30V5YH4
Polysorbate 80INACTIVE INGREDIENT6OZP39ZG8H4
POVIDONEINACTIVE INGREDIENTFZ989GH94E4
PROPANEINACTIVE INGREDIENTT75W9911L64
SODIUM CITRATEINACTIVE INGREDIENT1Q73Q2JULR4
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I4
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65AP4
TROLAMINEINACTIVE INGREDIENT9O3K93S3TK4

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 16 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42192-11242192-112-70

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 16 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 8 · 461 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
GLYCERINGLYCERINPDC6A3C0OXMOUTHWASH / BUCCAL100 mg/1mlExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSUPPOSITORY / RECTAL440 mgExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSOLUTION, CONCENTRATE / ORAL200 mg/1mlExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXOINTMENT / TOPICALNAExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXTABLET, CHEWABLE / ORAL12 mgExact identifier — unii candidate
75 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HSUSPENSION, EXTENDED RELEASE / ORAL40 mgExact identifier — unii candidate
78 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HSUSPENSION / RESPIRATORY (INHALATION)1 mgExact identifier — unii candidate
78 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HCONCENTRATE / ORAL1 mg/1mlExact identifier — unii candidate
78 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9IAEROSOL, FOAM / TOPICAL2.83 %w/wExact identifier — unii candidate
13 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET / ORAL216 mgExact identifier — unii candidate
30 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HTABLET, DELAYED RELEASE / ORAL4 mgExact identifier — unii candidate
78 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSUSPENSION / AURICULAR (OTIC)0.05 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL34 mgExact identifier — unii candidate
78 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9ICREAM / TOPICAL86000 mgExact identifier — unii candidate
13 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HCAPSULE, COATED PELLETS / ORAL2 mgExact identifier — unii candidate
78 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APCREAM / VAGINAL1088 mgExact identifier — unii candidate
26 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE / ORAL60 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IJELLY / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRATUMORADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HAEROSOL, FOAM / VAGINAL3 %w/wExact identifier — unii candidate
78 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9ITABLET, FILM COATED / ORAL2 mgExact identifier — unii candidate
13 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APSHAMPOO / TOPICAL9.7 %w/wExact identifier — unii candidate
26 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAOCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET, EXTENDED RELEASE / ORAL101 mgExact identifier — unii candidate
30 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HTABLET, COATED / ORAL18 mgExact identifier — unii candidate
78 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION, SUSPENSION / INTRAVENOUS0.5 %w/vExact identifier — unii candidate
78 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HSPRAY / NASAL0.01 mgExact identifier — unii candidate
78 equally ranked IID candidates
TROLAMINETROLAMINE9O3K93S3TKCREAM, AUGMENTED / TOPICAL20 mgExact identifier — unii candidate
22 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APEMULSION / TOPICALNAExact identifier — unii candidate
26 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET, CHEWABLE / ORAL48 mgExact identifier — unii candidate
30 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HCAPSULE, DELAYED RELEASE / ORAL23 mgExact identifier — unii candidate
78 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9IOINTMENT / OPHTHALMICNAExact identifier — unii candidate
13 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXCONCENTRATE / ORAL1800 mgExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSUSPENSION/ DROPS / ORAL750 mgExact identifier — unii candidate
75 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGRANULE, FOR SUSPENSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9IGRANULE / ORALNAExact identifier — unii candidate
13 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSOLUTION / TOPICAL1971 mgExact identifier — unii candidate
75 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APTABLET / BUCCAL6 mgExact identifier — unii candidate
26 equally ranked IID candidates
POLYOXYL 40 STEARATEPOLYOXYL 40 STEARATE TYPE I13A4J4NH9ILOTION / TOPICAL3 %w/wExact identifier — unii candidate
13 equally ranked IID candidates
Polysorbate 80POLYSORBATE 806OZP39ZG8HCAPSULE, COATED / ORAL0.04 mgExact identifier — unii candidate
78 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBARACHNOIDADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APPELLET / SUBCUTANEOUS0.97 mgExact identifier — unii candidate
26 equally ranked IID candidates
Polysorbate 20POLYSORBATE 207T1F30V5YHAEROSOL, FOAM / VAGINAL3 %w/wExact identifier — unii candidate
28 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ESOLUTION / OPHTHALMIC1.8 %w/vExact identifier — unii candidate
30 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXEMULSION / OPHTHALMIC3 mgExact identifier — unii candidate
75 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, LIQUID FILLED / ORAL1.5 mgExact identifier — unii candidate
174 equally ranked IID candidates
STEARIC ACIDSTEARIC ACID4ELV7Z65APTABLET / SUBLINGUAL9 mgExact identifier — unii candidate
26 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94EDROPS / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
PHENOXYETHANOLPHENOXYETHANOLHIE492ZZ3TCREAM / TOPICAL57 mgExact identifier — unii candidate
6 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
e1bfaddd-b6ba-4749-8c3a-6486cbe0e446cb0820e8-de07-4403-af3a-13986e86493e2024-05-21Warnings, Adverse reactionsExact identifier
spl id: e1bfaddd-b6ba-4749-8c3a-6486cbe0e446
spl set id: cb0820e8-de07-4403-af3a-13986e86493e

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.